TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03583372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: single daily dose 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebos
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebos
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: single daily dose of 4 mg
Study: NCT02685891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playing tones during deep sleep
Description: Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham condition
Description: in the sham condition, no tones will be played
Study: NCT03296787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.
Study: NCT03408951

Intervention type: OTHER
Intervention: Recording
Description: The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
Study: NCT03712501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 60 minute walk at 60% maximal oxygen uptake.
Study: NCT01248910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpine Skiing
Study: NCT04143620

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure
Description: Triple procedure
Study: NCT00831441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Tablets, Oral, 5 mg, twice daily, until study end

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, until study end
Study: NCT03119844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Phototherapy
Description: Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Phototherapy
Description: Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
Study: NCT03338114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT (orally disintigrating tablet)
Description: Oral Disintegrating Tablet
Study: NCT03982303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay102
Description: Hemay102 was administered through i.v. infusion for 4hrs.
Study: NCT03665779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: 70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
Study: NCT03119558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben (Neuraceq®) PET/MRI
Description: Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
Study: NCT01366898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasona, Idarubicine, ARA-C, Methotrexate
Study: NCT01559987

Intervention type: OTHER
Group type: OTHER
Intervention: Manual Toothbrush only
Description: ADA (American Dental Association) Reference Manual Toothbrush (MTB)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTB + Waterpik Ultra Water Flosser 'High'
Description: MTB + Waterpik Ultra Water Flosser 'High'

Intervention type: OTHER
Group type: OTHER
Intervention: MTB + Floss (MTB+Floss)
Description: MTB + Floss (MTB+Floss)
Study: NCT01046552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative ERCP and LC
Description: preoperative ERCP followed by LC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative ERCP and LC
Description: LC and intraoperative ERCP
Study: NCT01520636

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard physiotherapy
Description: daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental physiotherapy
Description: physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
Study: NCT05443100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC)
Description: Multidisciplinary rehabilitation program consisting of 10 WBC sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Multidisciplinary rehabilitation program consisting of diet and physical exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Multidisciplinary rehabilitation program consisting of diet and physical exercise.
Study: NCT03697330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood.
Study: NCT00979381

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: influenza vaccination

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: influenza vaccination

Intervention type: BIOLOGICAL
Intervention: influenza vaccine
Description: influenza vaccination
Study: NCT00845975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia Hearing Lasers #1 & #2
Description: Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lasers
Description: The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
Study: NCT04088123

Intervention type: DRUG
Intervention: Ticagrelor Oral Tablet [Brilinta]
Description: A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
Study: NCT04643340

Intervention type: OTHER
Intervention: real-time fMRI
Description: Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).

Intervention type: OTHER
Intervention: real-time fMRI
Description: Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
Study: NCT04320771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Study: NCT03687892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation
Description: Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
Study: NCT01168154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuterii
Description: Lactobacillus Reuterii 10000000000 CFU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02804425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: actor-spectator
Description: actor-spectator group : actor at least once during the simulation session
Study: NCT02748590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim II Neurostimulator Model 3058
Description: The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
Study: NCT02847897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 AcuPulse Laser
Description: Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
Study: NCT04396730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: 400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol Oil
Description: 400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Description: All participants will receive oral contraceptives

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptive pill
Description: All participants will receive oral contraceptives
Study: NCT03581357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mindfulness Meditation
Description: It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mindfulness Meditation
Description: It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
Study: NCT03041220

Intervention type: PROCEDURE
Intervention: cesarean section
Description: obese patients (BMI of 30 or greater) who have had a cesarean section
Study: NCT03581357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Coach
Description: It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Coach
Description: It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
Study: NCT02447185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation.
Study: NCT03055156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High rebound mattress toppers
Description: Patients will sleep on this mattress topper during their diagnostic sleep study.
Study: NCT02647671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin®
Description: 90 days of Aquamin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 90 days of Calcium Carbonate
Study: NCT03133117

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging (fMRI)
Study: NCT01280617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin 1.25mg/kg dose
Study: NCT02647671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 90 days of placebo
Study: NCT01280617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 0.75mg/kg dose
Description: Thymoglobulin
Study: NCT03346993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 5 MG/ML
Description: Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 5 MG/ML
Description: Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
Study: NCT02018120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Study: NCT03663543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Estrogen
Description: Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
Study: NCT03741062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J. Morita AdvErl Evo Er:YAG laser
Description: Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham treatment with laser unit turned off
Study: NCT02121431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P--Positive Parenting Program
Description: The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple P--Positive Parenting Program
Description: The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
Study: NCT03636984

Intervention type: DRUG
Intervention: recombinant TNF-α receptor: IgG Fc fusion protein
Description: 50mg weekly

Intervention type: DRUG
Intervention: recombinant TNF-α receptor: IgG Fc fusion protein
Description: 50mg weekly
Study: NCT01814631

Intervention type: OTHER
Intervention: image quality and resolution
Description: Image quality and resolution will be viewed using Aloka processor

Intervention type: OTHER
Intervention: image quality and resolution
Description: image quality and resolution will be viewed on the EU-me2
Study: NCT01797731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand-held surgical navigation system
Description: Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tibial extramedullary alignment system
Description: This is the standard of care for total knee arthroplasty.
Study: NCT04167982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral conventional-dose isotretinoin
Description: Conventional-dose isotretinoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral low-dose isotretinoin
Description: low-dose isotretinoin
Study: NCT03609879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Perfect ACE
Description: patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philly One-Peace Collar
Description: patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Necloc Collar
Description: patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexSplit Plus
Description: patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes